Abstract
We observed no association between neoplastic epithelial immunostainingfor either amphiregulin (AR) or heregulin (HRG) and presence of ER,EGFR/ERBB-2 overexpression, nodal status, or disease recurrence in 34 breastcarcinomas. However, stromal cell staining for both correlated with outcome;29% of stromal cell AR⊖ cases recurred vs. 85% forAR⊕ cases (p=0.001), and 41% of stromal cell HRG⊖cases recurred vs. 82% of HRG⊕ cases (p=0.01). Weconclude that both HRG and AR have significant biologic roles in breastcarcinoma growth or progression via mediation of host-tumor interactionswhich favor aggressive tumor behavior.
This is a preview of subscription content, log in via an institution to check access.
References
Shoyab M, Plowman GD, McDonald VL, Bradley JG, Todaro GJ: Structure and function of human amphiregulin: a member of the epidermal growth factor family. Science 24: 1074–1076, 1989
Normanno N, Ciardiello F, Brandt R, Salomon DS: Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. Breast Cancer Res Treat 29: 11–27, 1994
Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D, Yarden Y: Cell-type specific interaction of neu differentiation factor (NDF/heregulin) with neu/Her 2 suggests complex ligand-receptor relationships. EMBO J 12: 961–971, 1993
Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M: Ligand-specific activation of HER4/p180erb-B4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90: 1746–1750, 1993
Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carryway KL III: Coexpression of erbB-2 and erbB-3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269: 14661–14665, 1994
Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D, Tang C: The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat 38: 57–66, 1996
Marte BM, Jeschke M, Graus-Porta D, Taverna D, Hofer P, Groner B, Yarden Y, Hynes NE: Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells. Mol Endo 9: 14–23, 1995
Fiddes RJ, Janes PW, Sanderson GM, Sivertsen SP, Sutherland RL, Day RJ: Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells. Cell Growth and Differentiation 6: 1567–1577, 1995
Normanno N, Selvam MP, Qi C-F, Saeki T, Johnson G, Kim N, Ciardiello F, Shoyab M, Plowman G, Brandt R, Todaro G, Salomon DS: Amphiregulin as an autocrine growth factor for c-Ha-ras and c-erbB-2-transformed human mammary epithelial cells. Proc Natl Acad Sci USA 91: 2790–2794, 1994
Johnson GR, Saeki T, Gordon AW, Shoyab M, Salomon DS, Stromberg K: Autocrine action of amphiregulin in a colon carcinoma cell line and immuno-cytochemical localization of amphiregulin in human colon. J Cell Biol 118: 741–751, 1992
Normanno N, Kim N, Wen D, Smith K, Harris AL, Plowman G, Coletta G, Ciardiello F, Salomon DS: Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Res Treat 35: 293–297, 1995
Reddy KB, Mangold GL, Tandon AK, Yoneda T, Mundy GR, Zilberstein A, Osborne CK: Inhibition of breast cancer cell growth in vitro by tyrosine kinase inhibitor. Cancer Res 52: 3636–3641, 1992
Reddy KB, Yee D, Coffey RJ, Hilsenbeck SG, Osborne CK: Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor α expression. Cell Growth Differentiation 5: 1275–1282, 1994
Le Jeune S, Leek R, Horak E, Plowman G, Greenall M, Harris AL: Amphiregulin, epidermal growth factor receptor, and estrogen receptor expression in human primary breast cancer. Cancer Res 53: 3597–3602, 1993
Qi C-F, Liscia DS, Normanno N, Merlo G, Johnson GR, Gullick WJ, Ciardiello F, Saeki T, Brandt R, Kim N, Kenney N, Salomon DS: Expression of transforming growth factor α, amphiregulin and cripto-1 in human breast carcinomas. Br J Cancer 69: 903–910, 1994
Weidner N, Folkman J, Possa F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84(24): 1875–1887
Catellani R, Visscher DW, Wykes S, Sarkar FH, Crissman JD: Interaction of transforming growth factor-alpha and epidermal growth factor receptor in breast cancer. Cancer 73: 344–349, 1994
Shoyab M, McDonald VL, Bradley JG, Todaro GJ: Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci USA 85: 6528–6532, 1988
Plowman GD, Green JM, McDonald VL, Neubauer GM, Disteche CM, Todaro GJ, Shoyab M: The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 10: 1969–1981, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Visscher, D., Sarkar, F., Kasunic, T. et al. Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia . Breast Cancer Res Treat 45, 75–80 (1997). https://doi.org/10.1023/A:1005845512804
Issue Date:
DOI: https://doi.org/10.1023/A:1005845512804